Thermo Fisher Scientific's (TMO) broad-based improvement in Q2 is not enough to "meaningfully" chang

Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per share was 5.6% above analysts’ consensus estimates.

Companies in The News Are: TMO, TSLA, UNP, CSX

Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.

Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.

Thermo Fisher Scientific (NYSE:TMO) has been selected by ImmuPharma as the key drug product and contract development manufacturer for its Kapiglucagon diabetes treatment program. The partnership covers development and manufacturing support for Kapiglucagon, an experimental therapy aimed at addressing diabetes. This agreement adds a new project to Thermo Fisher Scientific’s pharmaceutical services portfolio, focused on complex drug development work. For investors tracking Thermo Fisher...

Thermo Fisher Scientific Inc. (NYSE:TMO) saw its share prices increase by 8.71 percent on Thursday to close at $572.32 apiece, as investors took heart from the strong earnings performance and a series of price target upgrades for its stock. In the second quarter of the year, the company grew its net income by 7 percent […]

Thermo Fisher Scientific (NYSE:TMO) reported stronger-than-expected second-quarter 2026 results and raised its full-year outlook, citing improving customer activity across end markets, broad-based growth and contributions from recent acquisitions. Chairman and Chief Executive Officer Marc Casper sa

Organic revenue beat guidance at 5% as pharma and biotech activity strengthened.

Thermo Fisher Scientific Inc (TMO) reports a 10% revenue increase and raises full-year guidance, driven by innovation and strategic acquisitions.

Shares of life sciences company Thermo Fisher (NYSE:TMO) jumped 9.7% in the afternoon session after the company reported strong second-quarter earnings that beat Wall Street's estimates for both profit and revenue. For the quarter, the company reported adjusted earnings per share of $6.03, topping expectations of $5.71. Revenue came in at $11.99 billion, a 10.5% year-over-year increase that surpassed Wall Street's forecasts of $11.72 billion. Organic revenue also grew by 5% year on year. Further

Thermo Fisher beats Q2 earnings and revenue estimates as organic growth and stronger customer activity lift results, sending shares higher in pre-market trading.

Thermo Fisher stock led a medtech rebound Thursday, easing investors' fears of continued malaise for the medical research and tools realm.

Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Thermo Fisher Scientific (NYSE:TMO) reported better-than-expected second-quarter earnings on Thursday, driven by improving customer activity across its end markets and continued organic growth. The stronger results lifted investor sentiment, sending the life sciences company’s shares more than 3% higher in premarket trading.

US equity markets were tracking in the red before the opening bell Thursday and oil prices rose amid

Thermo Fisher (TMO) delivered earnings and revenue surprises of +5.60% and +2.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com--On Thursday, Thermo Fisher Scientific Inc. (NYSE: TMO) reported second quarter results that exceeded analyst expectations, as the company demonstrated strengthening customer activity across its end markets.

Life sciences company Thermo Fisher (NYSE:TMO) announced better-than-expected revenue in Q2 CY2026, with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per share was 5.6% above analysts’ consensus estimates.

Dodge & Cox Fund, an investment management company, released its second-quarter 2026 investor letter for “Dodge and Cox Stock Fund”. A copy of the letter can be downloaded here. Despite volatile oil prices and rising inflation, U.S. equities reached record highs in Q2 2026, driven by a technology-led rally, particularly in memory semiconductors. The Fund’s […]

Life sciences company Thermo Fisher (NYSE:TMO) will be announcing earnings results this Thursday morning. Here’s what you need to know.

Seeing Machines (AIM:SEE) has won a new driver monitoring contract with a European carmaker worth around $5 million in lifetime revenue, just as new EU safety rules make the technology mandatory on new vehicles. Production starts in 2028, with the system built into a rear-view mirror for easy deployment across multiple platforms. Frontier IP (LSE:FIPP) says portfolio company Cambridge Raman Imaging has secured a €400,000 European grant to scale up its AI-powered pharmaceutical quality control technology. The company has also appointed a China-based distributor with over 100 customers globally. ImmuPharma (AIM:IMM) has appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon. That completes the main manufacturing partnerships alongside Swiss group Bachem, which is handling the active ingredient. MP Evans (AIM:MPE) grew crude palm oil production 11% to 192,300 tonnes in the first half, supported by higher harvests across its Indonesian estates. Pricing also held firm at around $873 per tonne. Ariana Resources (AIM:AAU) says its Tavşan gold mine in Türkiye has completed its ramp-up and is now processing ore at the required rate of at least 4,000 tonnes a day. Gold recovery is tracking at around 70%. 88 Energy (AIM:88E) has moved its Augusta-1 Alaska well closer to a first-quarter 2027 spud after securing a rig and camp. Prospective resources at South Prudhoe have also been upgraded by 35%. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy

Thermo Fisher Scientific’s board previously authorized a quarterly cash dividend of US$0.47 per share, paid on October 15, 2026, to shareholders of record on September 15, 2026. More recently, its Applied Biosystems RapidINTEL Plus Cartridge gained FBI approval for generating CODIS-searchable Rapid DNA crime scene profiles, expanding the company’s role in forensic workflows. We’ll now consider how FBI approval of Thermo Fisher’s RapidINTEL Plus Cartridge may influence the company’s...

Thermo Fisher Scientific stock has delivered a 32.0% gain over the past year, and the latest Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside relative to the current US$532.48 share price, while broader valuation checks point to a more mixed picture. The 32.0% return over the last 12 months suggests sentiment has been positive, raising the bar for what counts as good value today. On the upside, recent acquisitions and collaborations in areas like mRNA therapies...

Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.

This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.

TMO readies for second-quarter 2026 earnings, with growth expected across key segments as bioproduction, clinical research and new launches support results.

Intuitive Surgical heads into Q2 earnings with strong procedure momentum, da Vinci 5 adoption and expectations for another earnings beat despite margin pressures.

ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.

If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.